Viewing nowSitagliptin 25mg Tablets (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 28.34mg
Tablet · Prescription medication
Daehwa Pharmaceutical Co., Ltd.

MFDS item code 202102016 · Approved 2021.03.04 · Insurance code 645605590
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help control blood glucose levels in patients with type 2 diabetes. It can be administered alone, but in some cases, it can be used in combination with other hypoglycemic agents such as metformin, sulfonylureas, thiazolidinediones, and insulin for more effective blood glucose control. It particularly helps improve blood glucose levels when monotherapy is insufficient. It is used for blood glucose control in type 2 diabetes with various treatment strategies alongside.
Administer 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically during treatment with this medicine. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions; if symptoms such as skin rash or difficulty breathing occur after administration, it should be discontinued immediately, and a doctor should be consulted. Severe inflammation of the pancreas known as pancreatitis can occur, so if symptoms such as abdominal pain, vomiting, or nausea arise, stop taking this medication immediately and inform a healthcare provider. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor should it be taken by patients who are hypersensitive to this medication or its components. Patients with reduced kidney function may experience slower excretion of this medication, so it should be taken in a lower dosage, and kidney function tests should be performed regularly. During treatment, symptoms similar to a cold, headache, dyspepsia, and diarrhea may occur; consult a doctor if these symptoms persist or worsen. The risk of hypoglycemia increases when taken with other hypoglycemic agents, especially insulin or sulfonylureas, so blood glucose levels should be checked frequently and medication dosages adjusted as necessary. If severe or persistent joint pain occurs during treatment, it may be related to the medication, so consult a doctor to decide whether to discontinue it. Rarely, blistering similar to pemphigus may develop on the skin, so report any skin abnormalities to a healthcare provider immediately. The use of this medication in pregnant or breastfeeding women is not recommended, and its safety and efficacy have not been established in children under 18 years of age. In case of overdose, general treatment measures such as removal of the medication from the gastrointestinal tract are implemented, and, if necessary, hemodialysis can be used to remove the drug. This medication has a low potential for drug interactions, but it is important to consult a healthcare provider if taking other medications, especially for patients with heart or kidney disease.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory tract infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia accompanied by severe and disability, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from getting in, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness and prevents deterioration.
Bright yellow-orange round film-coated tablets
100 tablets/bottle, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 28.34mg
Tablet · Prescription medication
Daehwa Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.